Akili, Inc.

Equities

AKLI

US00974B1070

Advanced Medical Equipment & Technology

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
0.3925 ^USD	-1.88%		+60.20%	-19.42%

Apr. 30	Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	CI
Apr. 30	Akili, Inc. to Reduce Workforce	CI

Akili, Inc. announced that it has received $162 million in funding from a group of investors

August 18, 2022

On August 19, 2022, Akili, Inc. closed the transaction. the transaction included participation from returning investor PureTech Health plc for 500,000 share for gross proceeds of $5,000,000. As part of the transaction, Bharatt Chowrira of PureTech Health plc will join the company's board of directors.

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
PURETECH HEALTH PLC	219 GBX	+2.34%	+0.46%	743M
SOCL CAP	0.4016 USD	-1.76%	+63.92%	182M
AKILI, INC.	0.3925 USD	-1.88%	+60.20%	31.56M

Latest news about Akili, Inc.

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	Apr. 30	CI
Akili, Inc. to Reduce Workforce	Apr. 30	CI
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	Apr. 30	CI
Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Earnings Flash (AKLI) AKILI Posts Q4 Revenue $749,000, vs. Street Est of $0.78M	Feb. 29	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 26	MT
Akili Shares More Than Double After Submission of ADHD Treatment for Marketing Approval in Japan	Feb. 26	MT
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan	Feb. 26	DJ
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan	Feb. 26	CI
Akili Appoints John Spinale to the Board and Audit Committee	Feb. 21	CI
Akili, Inc. Announces Executive Changes, Effective on January 12, 2024	Jan. 05	CI
Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024	Jan. 05	CI
Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board	Dec. 20	CI
Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration	Dec. 18	CI
Transcript : Akili, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (AKLI) AKILI Reports Q3 Revenue $702,000	Nov. 09	MT
Akili, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Top Premarket Decliners	23-10-26	MT
Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce	23-10-12	CI
Akili Names Matt Franklin as Chief Executive, Eddie Martucci as Board Chair	23-10-06	MT
Akili, Inc. Announces Executive Changes	23-10-06	CI
Akili, Inc. Announces CEO Changes	23-10-06	CI
Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd	23-09-21	CI
Transcript : Akili, Inc. - Special Call	23-09-14

Chart Akili, Inc.

Duration

Period

More charts

Company Profile

Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Companyâs approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-13 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Akili, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4016 USD

Average target price

0.65 USD

Spread / Average Target

+61.85%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
AKILI, INC.	-19.42%	31.56M
THERMO FISHER SCIENTIFIC	+7.84%	218B
DANAHER CORPORATION	+7.35%	184B
INTUITIVE SURGICAL, INC.	+13.04%	135B
SIEMENS HEALTHINEERS AG	-0.15%	62.38B
EDWARDS LIFESCIENCES CORPORATION	+11.80%	51.37B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.81%	50.9B
AGILENT TECHNOLOGIES, INC.	+0.30%	40.87B
GE HEALTHCARE TECHNOLOGIES INC.	+2.78%	36.28B
RESMED, INC.	+26.14%	31.88B

Other Advanced Medical Equipment & Technology